ArticleOncoimmunology2015

NKT cell-targeted vaccination plus anti-4-1BB antibody generates persistent CD8 T cell immunity against B cell lymphoma.

Takumi Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.